Valuation: Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 1.04B 156M 142M 131M 119M 223M 14.56B 232M 1.59B 627M 7.86B 584M 572M 24.81B P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 817M 122M 112M 103M 93.18M 175M 11.44B 182M 1.25B 493M 6.18B 459M 450M 19.5B EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.91%
Yield 2024 *
-
Yield 2025 0.65%
10-29 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
08-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
04-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/10/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
08/09/25 Shanghai Rightongene Biotechnology's boards elects chairman RE
28/08/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
24/04/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/02/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25/02/25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
19/02/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
17/02/25 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
02/01/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
1 day-2.69%
1 week-12.54%
Current month-6.64%
1 month-15.98%
3 months-21.41%
6 months-35.16%
Current year-28.54%
1 week 18.52
Extreme 18.52000000
21.67
1 month 18.52
Extreme 18.52000000
22.85
Current year 17.81
Extreme 17.81
33.27
1 year 17.81
Extreme 17.81
33.27
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
86.39
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 21/07/2024
Director of Finance/CFO 34 26/01/2025
Investor Relations Contact - -
Director TitleAgeSince
Chairman 69 21/07/2024
Director/Board Member 41 12/05/2019
Director/Board Member 53 23/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
-2.69%-12.54%-35.62%-51.58% 160M
-0.22%-4.40%-19.63%+4.95% 181B
-1.56%-0.88%-0.08%+34.72% 125B
+0.19%-0.20%-11.51%+10.32% 121B
+1.12%-0.96%-41.94%+0.79% 90.52B
-0.64%-0.45%-3.69%+78.62% 66.9B
+0.31%+0.73%+12.35%-7.37% 58.68B
+1.19%-0.59%+4.22%+50.63% 54.38B
+0.66%-1.91%+3.64%+42.52% 48.46B
+0.84%+4.77%+3.97%-0.26% 35.4B
Average +0.16%-1.76%-8.83%+16.34% 78B
Weighted average by Cap. +0.38%-1.52%-9.90%+20.70%

Financials

2024 2025
Net sales 242M 36.33M 33.13M 30.63M 27.64M 52.06M 3.39B 54.12M 370M 146M 1.83B 136M 133M 5.79B 177M 26.58M 24.24M 22.41M 20.22M 38.09M 2.48B 39.59M 271M 107M 1.34B 99.7M 97.61M 4.23B
Net income -15.76M -2.36M -2.16M -1.99M -1.8M -3.39M -221M -3.52M -24.07M -9.51M -119M -8.87M -8.68M -376M -50.38M -7.55M -6.89M -6.37M -5.75M -10.82M -706M -11.25M -76.92M -30.4M -381M -28.33M -27.74M -1.2B
Net Debt -210M -31.53M -28.75M -26.59M -23.99M -45.19M -2.95B -46.97M -321M -127M -1.59B -118M -116M -5.02B -222M -33.35M -30.42M -28.12M -25.38M -47.8M -3.12B -49.68M -340M -134M -1.68B -125M -123M -5.31B
Projected Income Statement - Annual - Shanghai Rightongene Biotechnology Co., Ltd.
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production, sales, scientific research, and testing services of in vitro diagnostic products. The Company mainly provides self-branded molecular diagnostic reagents, scientific research services, testing services, and molecular testing equipment. The Company's main products are molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious disease related genes. The Company's main services include providing third-party medical testing services for various medical institutions, pharmaceutical companies, individual patients, and others, as well as providing genetic testing research services for research hospitals, pharmaceutical companies, scientific research institutions, third-party testing institutions and other enterprises and institutions.
Employees
327
Date Price Change Volume
18/11/26 CN¥18.83 -2.69% 970,400
17/11/26 CN¥19.35 -3.92% 1,035,138
16/11/26 CN¥20.14 -3.13% 924,748
13/11/26 CN¥20.79 -3.30% 825,156
12/11/26 CN¥21.50 -0.14% 964,965

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shanghai Rightongene Biotechnology Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 688217 Stock